Skip to main content
Back
AMGN logo

Amgen Inc.

Data quality: 100%
AMGN
NASDAQ Healthcare Drug Manufacturers - General
$349.77
▲ $1.97 (0.57%)
Mkt Cap: 188.55B
Day Range
$348.61 $353.42
52-Week Range
$261.43 $391.29
Volume
2,218,975
50D / 200D Avg
$359.42 / $316.58
Prev Close
$347.80

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 24.5 0.4
P/B 21.8 2.9
ROE % 106.1 3.8
Net Margin % 21.0 3.9
Rev Growth 5Y % 9.1 10.0
D/E 6.3 0.2

Key Takeaways

Revenue grew 9.05% annually over 5 years — modest growth
Earnings grew 88.53% over the past year
ROE of 106.10% indicates high profitability
Net margin of 20.99% shows strong profitability
Debt/Equity of 6.31 — high leverage
Generating 8.10B in free cash flow

Growth

Revenue Growth (5Y)
9.05%
Revenue (1Y)9.92%
Earnings (1Y)88.53%
FCF Growth (3Y)4.91%

Quality

Return on Equity
106.10%
ROIC12.66%
Net Margin20.99%
Op. Margin29.06%

Safety

Debt / Equity
6.31
Current Ratio1.14
Interest Coverage3.88

Valuation

P/E Ratio
24.45
P/B Ratio21.78
EV/EBITDA21.92
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9.92% Revenue Growth (3Y) 14.16%
Earnings Growth (1Y) 88.53% Earnings Growth (3Y) 7.14%
Revenue Growth (5Y) 9.05% Earnings Growth (5Y) 6.95%
Profitability
Revenue (TTM) 36.74B Net Income (TTM) 7.71B
ROE 106.10% ROA 8.51%
Gross Margin 70.80% Operating Margin 29.06%
Net Margin 20.99% Free Cash Flow (TTM) 8.10B
ROIC 12.66% FCF Growth (3Y) 4.91%
Safety
Debt / Equity 6.31 Current Ratio 1.14
Interest Coverage 3.88 Dividend Yield 0.03%
Valuation
P/E Ratio 24.45 P/B Ratio 21.78
P/S Ratio 5.13 PEG Ratio 0.26
EV/EBITDA 21.92 Dividend Yield 0.03%
Market Cap 188.55B Enterprise Value 234.02B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 36.74B 33.42B 28.19B 26.32B 25.98B
Net Income 7.71B 4.09B 6.72B 6.55B 5.89B
EPS (Diluted) 14.23 7.56 12.49 12.11 10.28
Gross Profit 26.01B 20.57B 19.78B 19.92B 19.53B
Operating Income 10.68B 7.26B 7.90B 9.57B 7.64B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 90.59B 91.84B 97.15B 65.12B 61.17B
Total Liabilities 81.93B 85.96B 90.92B 61.46B 54.47B
Shareholders' Equity 8.66B 5.88B 6.23B 3.66B 6.70B
Total Debt 54.60B 60.10B 64.61B 38.95B 33.31B
Cash & Equivalents 9.13B 11.97B 10.94B 7.63B 7.99B
Current Assets 29.06B 29.03B 30.33B 22.19B 19.39B
Current Liabilities 25.49B 23.10B 18.39B 15.69B 12.18B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Capital Light Compounder
#84 of 213
46
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#87 of 326
62

Recent Activity

Entered Capital Light Compounder
Mar 24, 2026
Entered Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026